Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy U Lin

Showing results (131-140 of 330) with videos related to

Pageof 33
Sort By:
NPJ Breast Cancer|March 30, 2023
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecanLaura Alder, Dario Trapani, Claire Bradbury, et al.
Cancer|May 1, 2012
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer NetworkNancy U Lin, Ann Vanderplas, Melissa E Hughes, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2011
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancerSandro Santagata, Rong Hu, Nancy U Lin, et al.
Clinical Breast Cancer|July 9, 2013
Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort studyInes Vaz-Luis, Davinia Seah, Erin M Olson, et al.
Cancer|March 12, 2015
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional studyInes Vaz-Luis, Melissa E Hughes, Angel M Cronin, et al.
The Oncologist|December 7, 2018
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic GradeOtto Metzger-Filho, Arlindo R Ferreira, Rinath Jeselsohn, et al.
Clinical Breast Cancer|July 2, 2020
Barriers to Clinical Trial Accrual: Perspectives of Community-Based ProvidersLauren P Knelson, Anthony R Cukras, Jennifer Savoie, et al.
Breast Cancer Research and Treatment|October 7, 2020
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancerOtto Metzger Filho, Anita Giobbie-Hurder, Nancy U Lin, et al.
American Journal of Clinical Pathology|December 17, 2023
HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancerDaniel Xia, Frank Kuo, Melissa Hughes, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2023
Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' toolJosé P Leone, Noah Graham, Julieta Leone, et al.
Pageof 33

Showing results (131-140 of 330) with videos related to

Sort By:
Pageof 33
NPJ Breast Cancer|March 30, 2023
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecanLaura Alder, Dario Trapani, Claire Bradbury, et al.
Cancer|May 1, 2012
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer NetworkNancy U Lin, Ann Vanderplas, Melissa E Hughes, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2011
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancerSandro Santagata, Rong Hu, Nancy U Lin, et al.
Clinical Breast Cancer|July 9, 2013
Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort studyInes Vaz-Luis, Davinia Seah, Erin M Olson, et al.
Cancer|March 12, 2015
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional studyInes Vaz-Luis, Melissa E Hughes, Angel M Cronin, et al.
The Oncologist|December 7, 2018
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic GradeOtto Metzger-Filho, Arlindo R Ferreira, Rinath Jeselsohn, et al.
Clinical Breast Cancer|July 2, 2020
Barriers to Clinical Trial Accrual: Perspectives of Community-Based ProvidersLauren P Knelson, Anthony R Cukras, Jennifer Savoie, et al.
Breast Cancer Research and Treatment|October 7, 2020
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancerOtto Metzger Filho, Anita Giobbie-Hurder, Nancy U Lin, et al.
American Journal of Clinical Pathology|December 17, 2023
HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancerDaniel Xia, Frank Kuo, Melissa Hughes, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2023
Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' toolJosé P Leone, Noah Graham, Julieta Leone, et al.
Pageof 33